Eppendorf grows faster than the market
During the first half of 2017, the Eppendorf Group achieved group sales of €327.9 million (prior-year period: €305.5 million). At 7.3% (6.6% when adjusted for currency effects), growth in sales lay above average market growth in the life science industry. Income from operations (EBIT) climbed 9.1% to €63.2 million (prior-year period: €58.0 million), amounting to an EBIT margin of 19.3% (prior year: 19.0%). All of the Eppendorf Group’s market regions and product groups contributed to this positive overall development.
Thomas Bachmann, President & CEO of Eppendorf AG, was very pleased at this positive development: “The mid-year result shows that we outperformed the market during the first half of this year. We are currently working on digitalizing our product portfolio and the connectivity of our devices with our new generation of networked products, which we launched on the market during the first six months of the year. We are assuming that our business will continue to develop positively overall for the whole year 2017 and we expect growth to be higher than the industry average.”
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
European_Society_of_Hypertension
Researchers enlist DNA to bring carbon nanotubes’ promise closer to reality - Tailored sequences of DNA lead to breakthrough in the campaign to sort and separate CNTs
Category:Australian_medical_associations

Taking antibiotics back in time - “Recreating such an ancient molecule was exhilarating, akin to bringing dinosaurs or wooly mammoths back to life”
